

Sister Study Breast Cancer Events (any type)<sup>1</sup> and Characteristics: Data Release 7.0<sup>2</sup>

Characteristic	N (total = 3,512) <sup>3</sup>	%
<b>Breast Cancer Subtype for 1st Diagnosis</b>		
Invasive <sup>4</sup>	2,637	75.1
Ductal only (no lobular component) <sup>5</sup>	1,880	53.5
Lobular only (no ductal component) <sup>5</sup>	232	6.6
Ductal and lobular <sup>5,6</sup>	174	5.0
Inflammatory <sup>7</sup>	6	0.2
Paget's <sup>8</sup>	10	0.3
Phyllodes <sup>9</sup>	5	0.1
Other/unknown if ductal or lobular <sup>10</sup>	330	9.4
<i>In situ</i>	851	24.2
Ductal only (no lobular component) <sup>11</sup>	711	20.2
Lobular only (no ductal component) <sup>11</sup>	108	3.1
Ductal and lobular <sup>6,11</sup>	16	0.5
Paget's <sup>8</sup>	5	0.1
Other/unknown if ductal or lobular	11	0.3
Invasiveness unknown <sup>12</sup>	24	0.7
<b>Stage at 1<sup>st</sup> Breast Cancer Diagnosis</b>		
0	757	24.5
I	1549	50.1
II	606	19.6
III	161	5.2
IV	21	0.7
<i>Unknown, missing, cannot stage</i>	418	
<b>Estrogen Receptor (ER) Status for 1st Breast Cancer Diagnosis</b>		
Positive	2,510	84.5
Negative	455	15.3
Borderline	5	0.2
<i>Unknown, missing, not performed</i>	542	
<b>Progesterone Receptor (PR) Status for 1st Breast Cancer Diagnosis</b>		
Positive	2,056	71.8
Negative	800	27.9
Borderline	7	0.2
<i>Unknown, missing, not performed</i>	649	
<b>HER2 Amplification Status for 1st Breast Cancer Diagnosis</b>		
Positive	320	13.1
Negative	2,089	85.4
Borderline	37	1.5
<i>Unknown, missing, not performed</i>	1,066	
<b>Combined ER, PR, HER2 Status</b>		
Triple negative	250	8.7
Not triple negative	2,630	91.3
<i>Unknown, missing, not performed</i>	632	

Characteristic	N (total = 3,512) <sup>3</sup>	%
<b>Race/Ethnicity<sup>13</sup></b>		
Non-Hispanic White	3,011	85.8
Non-Hispanic Black	270	7.7
Hispanic	131	3.7
Other	99	2.8
<i>Missing</i>	1	
<b>Age (in years) at Breast Cancer Diagnosis<sup>14</sup></b>		
Under 50	407	11.6
50-64	1695	48.3
65 and older	1410	40.1
<b>Menopausal Status at Breast Cancer Diagnosis</b>		
Pre-menopausal	629	18.0
Post-menopausal	2,873	82.0
<i>Unknown</i>	10	

Abbreviations: BrCa= Breast cancer; DCIS=Ductal carcinoma *in situ*; LCIS = Lobular carcinoma *in situ*; MR = Medical report (medical record and/or pathology report)

- <sup>1</sup> Breast cancer events (any type) are defined by the following ICD10 codes: D05 (includes lobular carcinoma in situ, ductal carcinoma in situ, other and unspecified *in situ* breast carcinomas), C50 (all invasive breast cancer), and D48.6 (neoplasm of uncertain behavior of breast)
- <sup>2</sup> Data release 7.0 includes events from follow-up phases that closed **on or before 9/15/2017**, excluding all data from participants who have withdrawn their data from the study (n=2). To be considered a breast cancer event, breast must be the primary site, and the cancer diagnosis must have occurred after the participant's baseline date. Consequently, Data Release 7.0 breast cancer events (any type) exclude a) through c) below:
- a) Breast cancers diagnosed prior to participant's baseline date. [Total (n=111): Invasive ductal (n=32); invasive lobular (n=1), invasive ductal and lobular (n=1), invasive, unknown if ductal or lobular (n=4), DCIS (n=19), LCIS (n=53), and *in situ* unknown if ductal or lobular (n=1)];
  - b) Breast cancers diagnosed with unknown timing relative to baseline [Total (n=10): Invasive, unknown if ductal or lobular (n=1), DCIS (n=2), and LCIS (n=7)];
  - c) Unknown primary cancer diagnoses where breast was unlikely to be the primary site, but the possibility could not be ruled out (n=3)
- <sup>3</sup> Confirmed by medical report (medical record or pathology report): 82.3% (n=2891) of reported breast cancer
- <sup>4</sup> Includes 'presumed invasive' (i.e. a carcinoma in situ with positive nodes)(n=1)
- <sup>5</sup> Ductal only, Lobular only, and Ductal and Lobular exclude inflammatory breast cancer and Paget's
- <sup>6</sup> Includes BrCa events with a) tumors with mixed ductal and lobular characteristics and/or b) multiple tumors of different histology (e.g. a ductal only tumor and a lobular only tumor)
- <sup>7</sup> Inflammatory – Ductal (n=5), Ductal and Lobular (n=1), Lobular(n=0)
- <sup>8</sup> Paget's - Invasive: Ductal (n=9), Lobular (n=1); *in situ*: Ductal (n=5), Lobular (n=0)
- <sup>9</sup> Phyllodes is neither ductal nor lobular; it is a sarcoma
- <sup>10</sup> Includes: a) Invasive but unknown if ductal or lobular (n=325); b) Invasive type "neither ductal nor lobular, not otherwise specified" (n=4); and c) Presumed invasive - *in situ* tumor, positive nodes (n=1); these are typically self-report without MR confirmation
- <sup>11</sup> Ductal only, Lobular only, and Ductal and Lobular exclude Paget's
- <sup>12</sup> Invasiveness unknown includes: a) Unknown if invasive or *in situ* and unknown if ductal or lobular (n=16); b) Ductal but unknown if invasive or *in situ* (n=4); c) Neither ductal nor lobular (other) but not otherwise specified and unknown if invasive or *in situ* (n=2); d) Per MR, unable to determine if DCIS or atypical ductal hyperplasia (n=2); and e) Per MR, unable to determine if LCIS or atypical lobular hyperplasia (n=0)
- <sup>13</sup> Race/ethnicity: precedence given to Hispanic ethnicity first, then Black race, then Other race, then White
- <sup>14</sup> For those missing age at diagnosis (n=20), age was imputed as the midpoint of the range of plausible ages at diagnosis